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Abstract : The present study investigated the effects of subconjunctival injec-
tions of an anti-rat vascular endothelial growth factor （anti-VEGF） antibody 
on oxygen-induced retinopathy （OIR） in a neonatal rat model.  OIR was 
induced by daily cycles of 80％ oxygen （20.5 h）, room air （0.5 h）, and a pro-
gressive return to 80％ oxygen （3 h） for 12 days ［until postnatal day （P） 12］.  
On P12, rats received subconjunctival injections in their right eye of 0.1 or 1.0 
μg anti-VEGF antibody （or 1.0μg goat IgG as a control）.  No injections 
were made into the left eye.  On P18, rats were killed and their retinas were 
removed and at-mounted before being stained with adenosine diphosphatase.  
Retinal neovascularization （NV） was scored and the extent of avascular areas, 
as a percentage of total retinal area （％AVA）, was determined using image 
analysis.  Although there was a tendency for lower mean NV scores in eyes 
injected with 0.1 and 1.0μg anti-VEGF compared with control （4.3±1.1, 2.3±
1.0, and 6.7±1.3, respectively ; n＝10–13）, the difference failed to reach statisti-
cal signicance.  Similarly, although there was a tendency for mean ％AVA to 
be lower in the injected eyes for both the 0.1 and 1.0μg anti-VEGF groups 
compared with control （15±3％, 13±3％, and 25±4％, respectively ; n＝
10–13）, the differences were not signicant.  Similar tendencies were observed 
in the contralateral eyes.  Although further studies using larger numbers of 
rats are needed to obtain statistically signicant results, the results of the pres-
ent study suggest that the subconjunctival injection of anti-VEGF antibody 
may prove to be a useful route of administration in conjunction with intra-
vitreal injections, which are the generally used method at present.  However, 
careful attention should be paid to the possibility of systemic side effects.
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Introduction
　In recent years, developments in perinatal care have contributed to decreased mortal-
ity among low birth-weight infants.  Consequently, the treatment rate for retinopathy of 
prematurity （ROP） has increased.  Despite current treatments, ROP remains a common, 
potentially blinding disease in babies who are born prematurely 1）.  Retinal photocoagulation, 
cryoretinopexy, scleral buckling, and vitreous surgery are established treatments for ROP2）; 
however, surgery for severe ROP, such as retinal detachment, has a less favorable progno-
sis3）.  Therefore, the prevention of ROP is extremely important and several studies have 
investigated ways in which to reduce ROP, such as the use of vitamin E prophylaxis4） and 
adjusting oxygen administration to newborns 5）.  Recent clinical studies of intravitreal injec-
tions of the anti-vascular endothelial growth factor （VEGF） antibody bevacizumab for the 
treatment of ROP have demonstrated good safety and efcacy in the short term for cases 
of severe ROP 6-8）.  In addition to these small-scale clinical studies6-8） using intravitreal beva-
cizumab for the treatment of ROP, bevacizumab is widely used to treat angiogenic disorders, 
including age-related macular degeneration, proliferative diabetic retinopathy, neovascular 
glaucoma, and macular edema related to retinal vein occlusion9, 10）.  However, intravitreal 
injections may result in several local complications, such as endophthalmitis, increased intra-
ocular pressure, retinal detachment, and intraocular hemorrhage.  Furthermore, intravitreal 
injections in infants carry a greater risk of lens centesis because infants have a relatively 
large lens volume for the eyeball.  In contrast, subconjunctival injections are associated with 
fewer local complications, and the technique is simple, safe, and amenable to rapid bedside 
administration.  Subconjunctival injections of bevacizumab have been reported in the treat-
ment of corneal neovascularization, pterygium, and bleb maintenance after ltering surgery 
for glaucoma11-13）; however, the use of subconjunctival bevacizumab for the treatment of 
ROP has not yet been reported.  Thus, in the present study we investigated the effects of 
the subconjunctival administration of anti-VEGF antibody on retinal neovascularization （NV） 
and avascular areas （AVA） in a rat oxygen-induced retinopathy （OIR） model of ROP.
Methods
Animal model
　All experiments were performed in accordance with the ARVO Statement for the Use of 
Animals in Ophthalmic and Vision Research : http://www.arvo.org/.  The Institutional Com-
mittee of Animal Care and Use at Showa University approved the study protocol.
　Female Sprague-Dawley rats at 14 days gestation were purchased from CLEA Japan 
（Tokyo, Japan）.  Rats were divided into two groups : those exposed to room air and those 
exposed to oxygen.  In both groups, 13 or 14 neonatal rats were kept with a dam in 
each cage after birth.  The dams were rotated between the room air- and oxygen-exposed 
groups every 2 days during the experimental period.  Retinal NV was induced in neonatal 
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rats using a standard protocol, as described previously 14, 15）.  The oxygen-exposed rats were 
exposed from birth until postnatal day （P） 12 to daily cycles of 80％ oxygen （20.5 h）, room 
air （30 min）, and a progressive return to 80％ oxygen （3 h） in an Oxycycler （Biosperix, 
Lacona, NY, USA）.  On P12, the oxygen-exposed rats were placed in room air until the 
end of experiments at P18 （Fig. 1）.
Treatment schedule
　On P12, rats were anesthetized with an intraperitoneal injection of a mixture of ketamine 
（15 mg / kg） and xylazine （25 mg / kg）.  The right eye was injected subconjunctivally with 0.1 
or 1.0μg anti-rat VEGF antibody （R&D Systems, Minneapolis, MN, USA） or 1.0μg normal 
goat IgG （R&D Systems） as a control.  The left eye was not injected （contralateral eye）.
Retinal processing
　On P18, some rats were killed by intraperitoneal injection of 100μL / 10 g body weight 
sodium pentobarbital （50 mg / mL）.  Both eyes were enucleated and then xed for 24–48 h 
in 4％ paraformaldehyde （Polyscience, Warrington, PA, USA） in 0.1 M cacodylate buffer, pH 
7.2 （Sigma, St. Louis, MO, USA）.  Anterior segments were removed and retinas with intact 
ora serratas were carefully dissected, with care taken to remove the hyaloid vessels and any 
remaining vitreous.  The retinas were stained with adenosine diphosphatase （ADPase） and 
at-mounted14）.  Digital images of ADPase-stained retinas were obtained using a camera 
and scanner （Nikon, Tokyo, Japan）, with retinal NV scored according to the method of 
Hasebe et al15）, e.g.  score 4 : long ridge, 3 : short ridge, 2 : ve or more glomerular buds, 
1 : less than ve glomerular buds, and 0 : none observed.  The AVA was also determined in 
ADPase-stained retinas as the mean percentage of total retinal area using image J software 
（National Institutes of Health, Bethesda, MD, USA）.
Fig. 1. Treatment schedule for the oxygen-induced retinopathy （OIR） 
model. Rats were exposed to daily cycles of 80％ oxygen （20.5 h）, 
room air （0.5 h）, and a progressive return to 80％ oxygen （3 h） 
until postnatal day （P） 12, and then placed in room air until P18. 
On P12, rats were administered a subconjunctival injection of anti-
vascular endothelial growth factor （VEGF） antibody.
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Fresh tissue preparation
　On P12, 3 h after anti-VEGF antibody treatment （P12＋3h）, as well as on P13, P14, and 
P18, rats were killed as described above.  Blood was collected from the left ventricle and 
plasma was obtained by centrifugation at 6,700×g for 5 min at 4℃.  Eyes were enucleated 
and the retinas were isolated under a microscope before being placed in 100μL tissue 
protein-extraction reagent （T-PER ; Thermo Fisher Scientific, Rockford, IL, USA） with a 
protease inhibitor cocktail （Sigma-Aldrich, St. Louis, MO, USA ; 1 : 100） for VEGF protein 
and goat IgG analysis.  The tissue was homogenized, centrifuged at 9,700×g for 15 min at 
4℃, and the lysate collected.  Lysate protein concentrations were determined using a BCA 
protein assay reagent kit （Thermo Fisher Scientific） with bovine plasma albumin as the 
standard.
Quantication of VEGF protein and IgG
　VEGF was assayed using a Quantikine rat VEGF Immunoassay kit （R&D Systems）, 
whereas the retinal and plasma concentrations of anti-rat VEGF goat antibody were 
determined using a goat IgG ELISA Quantitation Kit （BETHYL, Montgomery, TX, USA）. 
Both assays were performed in accordance with the manufacturers’ instructions.
Statistical analysis
　Statistical analyses were performed with the Kruskal-Wallis test or ANOVA.  All data are 
shown as the mean±SE.  Results were considered signicant at P＜0.05.
Results
　Body weight increased similarly in rats treated with 0.1 or 1.0μg anti-rat VEGF antibody 
（anti-VEGF） or 1.0μg IgG （control）.  OIR retinas exhibited neovascular changes and 
avascular areas （Fig. 2）.  The NV scores in the injected and contralateral eyes were 6.7±
4.7 and 7.2±2.5, respectively, in the control group （n＝10）, 4.3±3.1 and 4.2±3.0, respectively, 
in the 0.1μg anti-VEGF-injected group （n＝13 ; P＝0.07 vs. control）, and 2.3±1.6 and 2.8
±3.0, respectively, in the 1.0μg anti-VEGF-injected group （n＝12 ; P＝0.07 vs. control 
Fig. 3）.  Although there was a tendency for dose-dependent decreases in NV in both the 
injected and contralateral eyes in the antibody-injected groups, the differences failed to 
reach statistical signicance （P＝0.07）.  Similarly, there was a tendency for dose-dependent 
decreases in ％AVA in both the injected and contralateral eyes in the antibody-injected 
groups, but the differences were not statistically signicant （P＝0.07）.  Specically, ％AVA 
in the injected and contralateral eyes was 25±4％ and 25±4％, respectively, in the control 
group ; 15±3％ and 15±3％, respectively, in the 0.1 μg anti-VEGF-injected group ; and 13
±3％ and 12±3％, respectively, in the 1.0μg anti-VEGF-injected group （Fig. 4）.  In the 1.0 
μg anti-VEGF-injected group, there was a signicant increase in VEGF protein from P12 to 
P13 in OIR retinas following subconjunctival injections （from 86.6±43.0 to 544.4±54.9 pg /
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mg protein ; n＝3 ; P＝0.001）, as well as in the contralateral eye （516.2±169.9 pg / mg 
protein ; n＝3 ; P＝0.001）, but levels decreased on P14 in both the injected and contra-
lateral eyes （196.4±65.1 and 219.4±28.7 pg / mg protein, respectively ; n＝3 ; Fig. 5）.  Thus, 
the anti-VEGF injections did not affect VEGF levels in either eye.  In the retina, antibody 
concentrations in the injected and contralateral eyes increased gradually to 71.3±41.1 and 
92.5±54.4 ng / mL, respectively, on P13 （n＝4）, and to 76.7±38.3 and 101.7±51.0 ng / mL, 
respectively, on P14 （n＝3）.  On P18, the IgG concentrations in the injected and contralat-
eral eyes had decreased to 0 and 48.3±48.3 ng / mL, respectively （n＝3）.
Discussion
　Following subconjunctival injection, drugs must penetrate the sclera and choroid to affect 
eye function.  The molecular weight of anti-human VEGF antibodies for clinical ophthal-
mologic use is in the range 50–150 kDa, which means they are able to penetrate a human 
Fig. 2. Typical examples of flat-mounted adenosine diphosphatase 
（ADPase）-stained retinas on postnatal day （P） 18 in oxygen-
induced retinopathy （OIR）. （A） Control （1.0μg IgG-injected） 
eye （neovascularization （NV） score 7 ; extent of avascular areas 
as a percentage of total retinal area （％AVA） 40.4％）; （B） 0.1μg  
anti-vascular endothelial growth factor （VEGF） antibody-injected 
eye （NV score 10, ％AVA 15.5％）; and （C） 1.0μg anti-VEGF 
antibody-injected eye （NV score 0, ％AVA 0％）.
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sclera16）.  Subconjunctival anti-VEGF antibody injections should be particularly efcacious 
in infants because the sclera is thinner in infants’ eyes than in adults.  In the present study, 
the antibody concentration in the retina of the injected eye started to increase after injec-
tion of the antibody, peaking by 24 h.  However, the pharmacokinetics of the effects of the 
antibody on the retina following subconjunctival injection should take into consideration 
both drug penetration through the sclera and choroid, as well as drug delivery via the 
Fig. 3. Effects of subconjunctival injections of anti-vascular endothelial 
growth factor （VEGF） antibody on the neovascularization （NV） 
score in oxygen-induced retinopathy （OIR）. The NV score tended 
to decrease in a dose-dependent manner in both the injected and 
contralateral eyes （P＝0.07）. Data are the mean±SE （n＝10 in 
the control group ; n＝13 in the 0.1μg anti-VEGF group ; n＝12 
in the 1.0μg anti-VEGF group）.
Fig. 4. Effects of subconjunctival injections of anti-vascular endothelial 
growth factor （VEGF） antibody on the extent of avascular areas 
as a percentage of total retinal area （％AVA） in oxygen-induced 
retinopathy （OIR）. The ％AVA tended to decrease in a dose-
dependent manner in both the injected and contralateral eyes （P
＝0.07）. Data are the mean±SE （n＝10 in the control group ; n
＝13 in the 0.1μg anti-VEGF group ; n＝12 in the 1.0μg anti-
VEGF group）.
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systemic circulation.  For example, Nomoto et al have reported that plasma concentrations 
of bevacizumab increase immediately after subconjunctival administration in rabbits17）.  In 
the present study, antibody concentrations in the plasma had increased by 3 h after injec-
tion （data not shown）, and concentrations in the contralateral retina increased similar to 
those in the injected eye （Table 1）.  These results suggest that the injected antibody moves 
freely from the subconjunctiva to the systemic circulation and may thus influence other 
organs.  VEGF is an important physiological regulator of angiogenesis in health and dis-
esase18）.  Therefore, anti-VEGF antibody in the systemic circulation could potentially inhibit 
physiological angiogenesis in various organs in premature infants.  In the present study, 
subconjunctival injections of anti-rat VEGF antibody tended to reduce pathological retinal 
NV, suggesting that the antibody did not constrict the development of physiological retinal 
angiogenesis.  In fact, normal retinal vascular development was observed in all animals in 
Table 1.　The concentration of goat IgG in retina.
OIR
Postnatal Day Age
P12 P12＋3h P13 P14 P18
injected eye
（ng/mL）
0±0
（n＝3）
21.5±4.5
（n＝2）
71.3±41.1
（n＝4）
76.7±38.3
（n＝3）
0±0
（n＝3）
contralateral eye
（ng/mL）
0±0
（n＝3）
10.0±10.0
（n＝2）
92.5±54.4
（n＝4）
101.7±51.0
（n＝3）
48.3±48.3
（n＝3）
Fig. 5. Effects of subconjunctival injections of anti-vascular endothelial 
growth factor （VEGF） antibody on retinal VEGF content. VEGF 
levels increased significantly on postnatal day （P） 13 in both 
the antibody-injected （closed squares） and contralateral （closed 
triangles） eyes. Data are the mean±SE pg / mg protein ［n＝3 for 
each point except for the contralateral eye on P14 （n＝2） and 
P18 （n＝2）］. ＊＊P＜0.01 compared with P12 values each group.
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the room air-exposed groups （NV was not observed following subconjunctival injection of 
anti-rat VEGF ; data not shown）.  Geisen et al have reported no signicant difference in 
retinal AVA on P18 in a 50 / 10 OIR rat model compared with controls injected with anti-
rat VEGF antibody into the vitreous on P12 19）.  The antibody we used in the present study 
inhibits all isoforms of rat VEGF, and Ishida et al have reported that VEGF120 is necessary 
for the development of normal retinal vessels20）.  The antibody doses used in the present 
study were sufcient to control a pathological NV, but may not be effective in inhibiting the 
physiological development of retinal angiogenesis.  Lee et al suggested that intravitreal beva-
cizumab injection may be a safe and effective therapy at gestational ages of 34＋6 weeks, 
and that using bevacizumab before a gestational age of 32 weeks may inhibit peripheral 
retinal vasculogenesis21）.  Mintz-Hittner and Kuffel also reported that the growth of normal 
retinal vessels after intravitreal injection of bevacizumab is often slower than the growth 
seen in very premature infants 22）.  Therefore, the timing of bevacizumab treatment may be 
an important factor for peripheral retinal vasculogenesis.  Further investigations are needed 
to determine the effects of the anti-VEGF antibody on local organs and physiological devel-
opment in premature infants.  
　In conclusion, the results of the present study suggest that subconjunctival injections of 
anti-VEGF antibody decrease retinal NV and retinal AVA in a rat model of OIR.  A high-
er concentration of the anti-VEGF antibody treatment would make a signicant decrease 
retinal NV and retinal AVA.  It is necessary to investigate a dose increasing study in the 
future.  When administered via subconjunctival injections, anti-VEGF antibody may be trans-
ported systemically into the intraocular tissue of both the injected and contralateral eyes ; 
however, it may also induce local complications.  Further studies on the subconjunctival 
route of administration of anti-VEGF antibody, as an alternative to intravitreal administra-
tion, are needed to dene the appropriate dose and interval to minimize any systemic side 
effects.
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